Anticoagulants in AF Post-ICH: The Dilemma Continues
In patients with atrial fibrillation (AF) with a recent episode of intracranial hemorrhage (ICH), the use of oral anticoagulants significantly reduced net adverse clinical events — primarily driven by a reduced risk for ischemic stroke/systemic thromboembolism — but with an increased risk for recurrent ICH.
METHODOLOGY:
Oral anticoagulants prevent stroke in patients with AF, but their efficacy in those who have recently experienced an ICH remains unclear.
Researchers conducted a systematic literature review through March 2025 and performed an updated meta-analysis of randomized controlled trials comparing the use of oral anticoagulants with placebo or antiplatelets in patients with nonvalvular AF after a spontaneous ICH.
The analysis included 653 patients (weighted mean age, 78.2 years; 38% women; 95% White) from four trials with a low risk for bias, with follow-up durations ranging from a mean of 0.53 years to a median of 1.9 years.
The primary endpoint was net adverse clinical events — a composite of ischemic stroke/systemic thromboembolism, nonfatal myocardial infarction, cardiovascular death, recurrent ICH, and extracranial major bleeding.
TAKEAWAY:
The breakdown of oral anticoagulants used was 65% apixaban, 15% edoxaban, 14% dabigatran, 4% rivaroxaban, and 1% warfarin.
The use of oral anticoagulants reduced net adverse clinical events by 31% (relative risk [RR], 0.69; 95% CI, 0.52-0.93) and ischemic stroke/systemic thromboembolism by 76% (RR, 0.24; 95% CI, 0.09-0.61), translating into a number needed to treat of 12 and 8, respectively.
However, oral anticoagulants carried a more than threefold higher risk or recurrent ICH (RR, 3.20; 95% CI, 1.30-7.85), translating to a number needed to harm of 22.
There were no significant differences in fatal ischemic stroke, fatal ICH, major extracranial hemorrhage, myocardial infarction, or cardiovascular death on the basis of oral anticoagulant use.
IN PRACTICE:
'[This] meta-analysis informs shared decision-making between clinicians and patients, demonstrating a net clinical benefit of OACs [oral anticoagulants] predominantly through a reduction in ischemic stroke/systemic thromboembolism, while being cognizant of an increased risk of recurrent ICH,' the researchers wrote.
'The magnitude of benefit and risk may differ across ICH subtypes and with the timing of OACs initiation, warranting further investigation through [individual patient data] meta-analysis,' they further added.
SOURCE:
This study was led by Kuan-Yu Chi, MD, and Pei-Lun Lee, MD, of Jacobi Medical Center, Albert Einstein College of Medicine in New York City, and Yu Chang, MD, of the National Cheng Kung University in Tainan, Taiwan. It was published online on July 21, 2025, in the Journal of the American College of Cardiology.
LIMITATIONS:
This study lacked individual patient data, which prevented deeper analyses such as timing of events. The number of included trials and participants were insufficient to detect the effects on outcomes that occurred less frequently. All the included trials had an open-label design.
DISCLOSURES:
Three authors reported receiving research funding and awards from various sources including the Johns Hopkins University Claude D. Pepper Older Americans Independence Center funded by the National Institute on Aging; National Heart, Lung, and Blood Institute; and National Institutes of Health National Institute of Aging. One author reported serving as a consultant for Novo Nordisk, Merck, and HeartFlow, Inc.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 days ago
- Medscape
Social Factors Affect Access to RSV Prophylaxis in Children
TOPLINE: Only about one third of eligible children born outside the typical respiratory syncytial virus (RSV) season received nirsevimab, a monoclonal antibody for RSV prophylaxis. Older age, Black race, and public insurance were associated with reduced rates of receipt. METHODOLOGY: Researchers conducted a retrospective study to examine how many children born outside the typical RSV season (October to March) received nirsevimab and which factors influenced its receipt, such as age, race, insurance type, and residing in low- vs high-opportunity areas (measured by an index indicating neighborhood features that support child development). They included children younger than 8 months who received care across 32 pediatric primary care practices in Pennsylvania and New Jersey, all of which had nirsevimab available. A total of 7208 eligible children born between April and September 2023 (average age at the start of RSV season, 3.5 months; 49% girls; 51.3% White) were included. All had at least one visit to primary care within 14 days of birth and at least one visit after reaching 8 months of age or after the RSV season ended. TAKEAWAY: Overall, 35% of eligible children received nirsevimab, and uptake varied by practice from 20% to 65%. Of those who received nirsevimab, 53.1% were White and 64.4% had private insurance. Older age was associated with reduced odds of receiving nirsevimab (adjusted odds ratio [aOR], 0.60; 95% CI, 0.58-0.62 for each additional month). Children with low weight at birth had higher odds of receiving nirsevimab (aOR, 1.43; 95% CI, 1.13-1.82). Children who were Black vs White (aOR, 0.53; 95% CI, 0.43-0.65), with public vs private insurance (aOR, 0.79; 95% CI, 0.67-0.92), and living in very low- vs very high-opportunity areas (aOR, 0.70; 95% CI, 0.54-0.91) had significantly lower odds of receiving nirsevimab. Among children fully vaccinated against diphtheria, Haemophilus influenzae type B, poliovirus, Streptococcus pneumoniae, tetanus, and pertussis, 38.7% received nirsevimab. IN PRACTICE: 'The identification of sociodemographic factors associated with receipt of nirsevimab emphasizes the importance of examining the drivers of these disparities to inform interventions designed to ensure more equitable uptake so that all children are protected from RSV,' the authors of the study concluded. SOURCE: This study was led by Mahaa M. Ahmed, MS, of the Clinical Futures at Children's Hospital of Philadelphia in Philadelphia. It was published online on July 17, 2025, in Pediatrics. LIMITATIONS: The data represented practices in only one care network, and the findings may not be generalizable. Infants entering their first RSV season were included, which prevented the evaluation of nirsevimab uptake among children at high risk entering their second season of RSV. This retrospective study used electronic health records and could not capture family preferences, knowledge of nirsevimab, or interactions between families and clinicians during vaccination opportunities. DISCLOSURES: This study received support from the Infectious Diseases Society of America's Grants for Emerging Researchers/Clinicians Mentorship program and the Pediatric Infectious Diseases Society's Supporting Research and Promoting Pediatric ID program. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
4 days ago
- Medscape
Family History Shapes Psoriatic Disease Onset in PsA
TOPLINE: Patients with psoriatic arthritis (PsA) who had a family history of psoriatic disease were diagnosed with psoriasis and PsA earlier and showed more entheseal involvement than those without such family history. METHODOLOGY: Researchers enrolled 843 patients with PsA (mean age, 50.8 years; 50.6% men; 76.4% White individuals) from the New York University (NYU) Psoriatic Arthritis Center and associated clinics in an observational, longitudinal registry to study familial aggregation and differences in disease onset and phenotype. They collected data on demographics, medical and family history, and psoriatic phenotype and activity. Patients were categorized on the basis of family history, with 379 participants having one or more first-degree or second-degree relatives with psoriatic disease (301 had relatives with psoriasis, and 78 had relatives with PsA) and 464 having no history. Disease measures included the age at which psoriasis and PsA were diagnosed, types and locations of psoriasis, and areas affected by PsA. TAKEAWAY: Patients with a family history of psoriatic disease were diagnosed with psoriasis and PsA earlier than those without (mean age, 27.6 vs 32.2 years and 37.6 vs 40.3 years, respectively; P < .01 for both). Patients with first-degree or second-degree relatives with PsA were diagnosed with psoriasis and PsA earlier than those with relatives with psoriasis alone or no family history (P < .01 and P = .01, respectively). Patients with a family history of psoriatic disease were more likely to have a history of enthesitis than those without (36.7% vs 30.0%; P < .05) and active enthesitis at baseline (30.1% vs 21.6%; P < .01). The transition time between the diagnosis of psoriasis and PsA was longer among patients with two or more first-degree or second-degree relatives than among those with only one relative or those with no family history (mean time to diagnosis, 14.1 vs 8.0 vs 8.8 years; P < .01). IN PRACTICE: 'Additional studies integrating molecular and immune features are needed to elucidate how genetic, environmental, and epigenetic elements influence the progression from psoriasis to PsA, as well as PsA's clinical presentation, severity, and therapeutic response,' the authors of the study wrote. SOURCE: The study was led by Catherine Howe, MD, NYU Grossman School of Medicine, New York City. It was published online on July 14, 2025, in Arthritis & Rheumatology. LIMITATIONS: The study relied on patient-reported data for age of diagnosis and family history, which may introduce potential recall bias and underdiagnosis of mild cases. Having a family history may not equate to genetic burden. The lack of a uniform baseline visit for all patients with PsA may affect the assessment of disease activity. DISCLOSURES: This study was funded by grants to authors from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the NYU Colton Center for Autoimmunity, the Rheumatology Research Foundation, the National Psoriasis Foundation, and other sources. Two authors reported receiving support from an Institutional National Research Service Award and the National Institute of Diabetes and Digestive and Kidney Diseases. Some authors reported receiving consulting fees from or serving on advisory boards for pharmaceutical companies that market drugs for psoriatic disease. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
4 days ago
- Yahoo
Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies
(Reuters) -Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases. Matchpoint said on Thursday it will use its technology to develop drugs that block the activity of a specific protein, helping to lower the production of inflammation-causing signals. The company will lead the research and drug development process, using the funding from Novartis. If Novartis exercises its option to exclusively license the program, the drugmaker will have global rights to develop and commercialize all products resulting from the collaboration. Matchpoint said it will receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, and development and commercial milestones. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
